Increased nuchal translucency with normal karyotype and anomaly scan: What next?

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 28, Issue 3, 2014, Pages 355-366

  Bakker, Merel ^a   Pajkrt, Eva ^b   Bilardo, Caterina M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

developmental delay; increased nuchal translucency; normal karyotype; prenatal screening

Indexed keywords

B RAF KINASE; K RAS PROTEIN; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAF PROTEIN; SOS PROTEIN;

AUTOSOMAL DOMINANT DISORDER; CHROMOSOME ABERRATION; COMPARATIVE GENOMIC HYBRIDIZATION; CONGENITAL HEART MALFORMATION; COPY NUMBER VARIATION; DEVELOPMENTAL DISORDER; FETUS DEATH; FETUS HEART; FIRST TRIMESTER PREGNANCY; GENETIC ALGORITHM; GENETIC COUNSELING; GENETIC DISORDER; GESTATIONAL AGE; HIGH RISK PREGNANCY; HUMAN; KARYOTYPE; KARYOTYPING; MACROSOMIA; META ANALYSIS (TOPIC); MISSENSE MUTATION; NOONAN SYNDROME; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY OUTCOME; PRENATAL SCREENING; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; SMITH LEMLI OPITZ SYNDROME; SPINAL MUSCULAR ATROPHY; SPONTANEOUS ABORTION; SYSTEMATIC REVIEW (TOPIC);

DEVELOPMENTAL DELAY; INCREASED NUCHAL TRANSLUCENCY; NORMAL KARYOTYPE; PRENATAL SCREENING;

ALGORITHMS; CONGENITAL ABNORMALITIES; DEVELOPMENTAL DISABILITIES; DOWN SYNDROME; FEMALE; HUMANS; KARYOTYPE; NOONAN SYNDROME; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND;

EID: 84897057121     PISSN: 15216934     EISSN: 15321932     Source Type: Journal    
DOI: 10.1016/j.bpobgyn.2013.10.004     Document Type: Article

References (98)

1. Nicolaides KH, Azar G, Byrne D, et al. Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy. BMJ 1992;304:867-9.
2. Bilardo CM, Pajkrt E, de Graaf I, et al. Outcome of fetuses with enlarged nuchal translucency and normal karyotype. Ultrasound Obstet Gynecol 1998;11:401-6. (Pubitemid 28344741)
3. Souka AP, Snijders RJ, Novakov A, et al. Defects and syndromes in chromosomally normal fetuses with increased nuchal translucency thickness at 10-14 weeks of gestation. Ultrasound Obstet Gynecol 1998;11:391-400. (Pubitemid 28344740)
4. Ville Y. Nuchal translucency in the first trimester of pregnancy: ten years on and still a pain in the neck? Ultrasound Obstet Gynecol 2001;18:5-8. (Pubitemid 32664643)
5. Bilardo CM, Timmerman E, Pajkrt E, et al. Increased nuchal translucency in euploid fetuses - what should we be telling the parents? Prenat Diagn 2010;30:93-102.
6. Bilardo CM, Muller MA, Pajkrt E, et al. Increased nuchal translucency thickness and normal karyotype: time for parental reassurance. Ultrasound Obstet Gynecol 2007;30:11-8. (Pubitemid 47074846)
7. Seror V, Ville Y. Prenatal screening for Down syndrome: women's involvement in decision-making and their attitudes to screening. Prenat Diagn 2009;29:120-8.
8. Gidiri M, McFarlane J, Holding S, et al. Maternal serum screening for Down syndrome: are women's perceptions changing? BJOG 2007;114:458-61. (Pubitemid 46393303)
9. Ekelund CK, Petersen OB, Skibsted L, et al. First-trimester screening for trisomy 21 in Denmark: implications for detection and birth rates of trisomy 18 and trisomy 13. Ultrasound Obstet Gynecol 2011;38:140-4.
10. Maxwell S, Brameld K, Bower C, et al. Socio-demographic disparities in the uptake of prenatal screening and diagnosis in Western Australia. Aust N Z J Obstet Gynaecol 2011;51:9-16.
11. Bakker M, Birnie E, Pajkrt E, et al. Low uptake of the combined test in The Netherlands - which factors contribute? Prenat Diagn 2012;32:1305-12.
12. Shantha N, Granger K, Arora P, et al. Women's choice for Down's screening: a comparative experience in three district general hospitals. Eur J Obstet Gynecol Reprod Biol 2009;146:61-4.
13. Muller MA, Bleker OP, Bonsel GJ, et al. Women's opinions on the offer and use of nuchal translucency screening for Down syndrome. Prenat Diagn 2006;26:105-11. (Pubitemid 43287091)
14. Favre R, Moutel G, Duchange N, et al. What about informed consent in first-trimester ultrasound screening for Down syndrome? Fetal Diagn Ther 2008;23:173-84. (Pubitemid 351555838)
15. Snijders RJ, Noble P, Sebire N, et al. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 1998;352:343-6. (Pubitemid 28352196)
16. Cha'ban FK, Van Splunder P, Los FJ, et al. Fetal outcome in nuchal translucency with emphasis on normal fetal karyotype. Prenat Diagn 1996;16:537-41. (Pubitemid 26187704)
17. Saldanha FA, Brizot Mde L, Moraes EA, et al. Increased fetal nuchal translucency thickness and normal karyotype: prenatal and postnatal follow-up. Rev Assoc Med Bras 2009;55:575-80.
18. Senat MV, De Keersmaecker B, Audibert F, et al. Pregnancy outcome in fetuses with increased nuchal translucency and normal karyotype. Prenat Diagn 2002;22:345-9. (Pubitemid 34538557)
19. Pajkrt E, Bilardo CM, Van Lith JM, et al. Nuchal translucency measurement in normal fetuses. Obstet Gynecol 1995;86:994-7. (Pubitemid 27331500)
20. Souka AP, Von Kaisenberg CS, Hyett JA, et al. Increased nuchal translucency with normal karyotype. Am J Obstet Gynecol 2005;192:1005-21. (Pubitemid 40487772)
21. Lam YH, Tang MH, Lee CP, et al. The effect of fetal gender on nuchal translucency at 10-14 weeks of gestation. Prenat Diagn 2001;21:627-9. (Pubitemid 32843917)
22. Larsen SO, Wojdemann KR, Shalmi AC, et al. Gender impact on first trimester markers in Down syndrome screening. Prenat Diagn 2002;22:1207-8. (Pubitemid 36043170)
23. Yaron Y, Wolman I, Kupferminc MJ, et al. Effect of fetal gender on first trimester markers and on Down syndrome screening. Prenat Diagn 2001;21:1027-30. (Pubitemid 34056184)
24. Spencer K, Ong CY, Liao AW, et al. The influence of fetal sex in screening for trisomy 21 by fetal nuchal translucency, maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 2000;20:673-5. (Pubitemid 30598916)
25. Timmerman E, Pajkrt E, Bilardo CM. Male gender as a favorable prognostic factor in pregnancies with enlarged nuchal translucency. Ultrasound Obstet Gynecol 2009;34:373-8.
26. Haak MC, van Vugt JM. Pathophysiology of increased nuchal translucency: a review of the literature. Hum Reprod Update 2003;9:175-84. (Pubitemid 36582605)
27. Ghi T, Huggon IC, Zosmer N, et al. Incidence of major structural cardiac defects associated with increased nuchal translucency but normal karyotype. Ultrasound Obstet Gynecol 2001;18:610-4. (Pubitemid 34063060)
28. Galindo A, Comas C, Martinez JM, et al. Cardiac defects in chromosomally normal fetuses with increased nuchal translucency at 10-14 weeks of gestation. J Matern Fetal Neonatal Med 2003;13:163-70. (Pubitemid 36384516)
29. Hyett J. Does nuchal translucency have a role in fetal cardiac screening? Prenat Diagn 2004;24:1130-5. (Pubitemid 40053036)
30. Haak MC, Twisk JW, Bartelings MM, et al. First-trimester fetuses with increased nuchal translucency do not show altered intracardiac flow velocities. Ultrasound Obstet Gynecol 2005;25:246-52. (Pubitemid 40432691)
31. Huggon IC, Turan O, Allan LD. Doppler assessment of cardiac function at 11-14 weeks' gestation in fetuses with normal and increased nuchal translucency. Ultrasound Obstet Gynecol 2004;24:390-8. (Pubitemid 39179473)
32. Bilardo CM, Muller MA, Zikulnig L, et al. Ductus venosus studies in fetuses at high risk for chromosomal or heart abnormalities: relationship with nuchal translucency measurement and fetal outcome. Ultrasound Obstet Gynecol 2001;17:288-94. (Pubitemid 32417441)
33. Clur SA, Oude Rengerink K, Mol BW, et al. Fetal cardiac function between 11 and 35 weeks' gestation and nuchal translucency thickness. Ultrasound Obstet Gynecol 2011;37:48-56.
34. Hyett J,Moscoso G, Papapanagiotou G, et al. Abnormalities of the heart and great arteries in chromosomally normal fetuses with increased nuchal translucency thickness at 11-13 weeks of gestation. Ultrasound Obstet Gynecol 1996;7:245-50. (Pubitemid 126720343)
35. Hyett JA, Perdu M, Sharland GK, et al. Increased nuchal translucency at 10-14 weeks of gestation as a marker for major cardiac defects. Ultrasound Obstet Gynecol 1997;10:242-6. (Pubitemid 27485319)
36. Bekker MN, Haak MC, Rekoert-Hollander M, et al. Increased nuchal translucency and distended jugular lymphatic sacs on first-trimester ultrasound. Ultrasound Obstet Gynecol 2005;25:239-45. (Pubitemid 40432690)
37. Bekker MN, van den Akker NM, Bartelings MM, et al. Nuchal edema and venous-lymphatic phenotype disturbance in human fetuses and mouse embryos with aneuploidy. J Soc Gynecol Investig 2006;13:209-16.
38. de Mooij YM, van den Akker NM, Bekker MN, et al. Aberrant lymphatic development in euploid fetuses with increased nuchal translucency including Noonan syndrome. Prenat Diagn 2011;31:159-66.
39. Brand-Saberi B, Floel H, Christ B, et al. Alterations of the fetal extracellular matrix in the nuchal oedema of Down's syndrome. Ann Anat 1994;176:539-47. (Pubitemid 24368870)
40. von Kaisenberg CS, Krenn V, Ludwig M, et al. Morphological classification of nuchal skin in human fetuses with trisomy 21, 18, and 13 at 12-18 weeks and in a trisomy 16 mouse. Anat Embryol (Berl) 1998;197:105-24.
41. Bohlandt S, von Kaisenberg CS, Wewetzer K, et al. Hyaluronan in the nuchal skin of chromosomally abnormal fetuses. Hum Reprod 2000;15:1155-8. (Pubitemid 30251317)
42. Nakamura T, Gulick J, Pratt R, et al. Noonan syndrome is associated with enhanced pERK activity, the repression of which can prevent craniofacial malformations. Proc Natl Acad Sci U S A 2009;106:15436-41.
43. Kagan KO, Avgidou K, Molina FS, et al. Relation between increased fetal nuchal translucency thickness and chromosomal defects. Obstet Gynecol 2006;107:6-10.
44. Hillman SC, Pretlove S, Coomarasamy A, et al. Additional information from array comparative genomic hybridization technology over conventional karyotyping in prenatal diagnosis: a systematic review and meta-analysis. Ultrasound Obstet Gynecol 2011;37:6-14.
45. Leung TY, Vogel I, Lau TK, et al. Identification of submicroscopic chromosomal aberrations in fetuses with increased nuchal translucency and apparently normal karyotype. Ultrasound Obstet Gynecol 2011;38:314-9.
46. Clur SA, Mathijssen IB, Pajkrt E, et al. Structural heart defects associated with an increased nuchal translucency: 9 years experience in a referral centre. Prenat Diagn 2008;28:347-54. (Pubitemid 351519076)
47. Maymon R, Herman A. The clinical evaluation and pregnancy outcome of euploid fetuses with increased nuchal translucency. Clin Genet 2004;66:426-36. (Pubitemid 39429739)
48. Westin M, Saltvedt S, Almstrom H, et al. By how much does increased nuchal translucency increase the risk of adverse pregnancy outcome in chromosomally normal fetuses? A study of 16,260 fetuses derived from an unselected pregnant population. Ultrasound Obstet Gynecol 2007;29:150-8. (Pubitemid 46326587)
49. Lopes LM, Brizot ML, Lopes MA, et al. Structural and functional cardiac abnormalities identified prior to 16 weeks' gestation in fetuses with increased nuchal translucency. Ultrasound Obstet Gynecol 2003;22:470-8. (Pubitemid 37500693)
50. Mavrides E, Cobian-Sanchez F, Tekay A, et al. Limitations of using first-trimester nuchal translucency measurement in routine screening for major congenital heart defects. Ultrasound Obstet Gynecol 2001;17:106-10.
51. Michailidis GD, Economides DL. Nuchal translucency measurement and pregnancy outcome in karyotypically normal fetuses. Ultrasound Obstet Gynecol 2001;17:102-5.
52. Hyett J, Perdu M, Sharland G, et al. Using fetal nuchal translucency to screen for major congenital cardiac defects at 10-14 weeks of gestation: population based cohort study. BMJ 1999;318:81-5. (Pubitemid 29188923)
53. Simpson JM, Sharland GK. Nuchal translucency and congenital heart defects: heart failure or not? Ultrasound Obstet Gynecol 2000;16:30-6. (Pubitemid 33108683)
54. Makrydimas G, Sotiriadis A, Ioannidis JP. Screening performance of first-trimester nuchal translucency for major cardiac defects: a meta-analysis. Am J Obstet Gynecol 2003;189:1330-5. (Pubitemid 37542168)
55. Muller MA, Clur SA, Timmerman E, et al. Nuchal translucency measurement and congenital heart defects: modest association in low-risk pregnancies. Prenat Diagn 2007;27:164-9. (Pubitemid 46293938)
56. Sotiriadis A, Papatheodorou S, Eleftheriades M, et al. Nuchal translucency and major congenital heart defects in fetuses with normal karyotype: a meta-analysis. Ultrasound Obstet Gynecol 2013;42:383-9.
57. Wald NJ, Morris JK, Walker K, et al. Prenatal screening for serious congenital heart defects using nuchal translucency: a meta-analysis. Prenat Diagn 2008;28:1094-104.
58. Timmerman E, Pajkrt E, Maas SM, et al. Enlarged nuchal translucency in chromosomally normal fetuses: strong association with orofacial clefts. Ultrasound Obstet Gynecol 2010;36:427-32.
59. Scott F, Evans J, McLennan A. Perinatal outcome in fetuses with extremely large nuchal translucency measurement. Aust N Z J Obstet Gynaecol 2009;49:254-7.
60. Maymon R, Zimerman AL, Weinraub Z, et al. Correlation between nuchal translucency and nuchal skin-fold measurements in Down syndrome and unaffected fetuses. Ultrasound Obstet Gynecol 2008;32:501-5.
61. Hiippala A, Eronen M, Taipale P, et al. Fetal nuchal translucency and normal chromosomes: a long-term follow-up study. Ultrasound Obstet Gynecol 2001;18:18-22.
62. Lee KA, Williams B, Roza K, et al. PTPN11 analysis for the prenatal diagnosis of Noonan syndrome in fetuses with abnormal ultrasound findings. Clin Genet 2009;75:190-4.
63. Pergament E, Alamillo C, Sak K, et al. Genetic assessment following increased nuchal translucency and normal karyotype. Prenat Diagn 2011;31:307-10.
64. Tartaglia M, Mehler EL, Goldberg R, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 2001;29:465-8. (Pubitemid 34326699)
65. Jorge AA, Malaquias AC, Arnhold IJ, et al. Noonan syndrome and related disorders: a review of clinical features and mutations in genes of the RAS/MAPK pathway. Horm Res 2009;71:185-93.
66. Croonen EA, Nillesen WM, Stuurman KE, et al. Prenatal diagnostic testing of the Noonan syndrome genes in fetuses with abnormal ultrasound findings. Eur J Hum Genet 2013;21:936-42.
67. Houweling AC, de Mooij YM, van der Burgt I, et al. Prenatal detection of Noonan syndrome by mutation analysis of the PTPN11 and the KRAS genes. Prenat Diagn 2010;30:284-6.
68. van der Burgt I, Thoonen G, Roosenboom N, et al. Patterns of cognitive functioning in school-aged children with Noonan syndrome associated with variability in phenotypic expression. J Pediatr 1999;135:707-13. (Pubitemid 30180419)
69. Bakker M, Pajkrt E, Mathijssen IB, et al. Targeted ultrasound examination and DNA testing for Noonan syndrome, in fetuses with increased nuchal translucency and normal karyotype. Prenat Diagn 2011;31:833-40.
70. Sotiriadis A, Papatheodorou S, Makrydimas G. Neurodevelopmental outcome of fetuses with increased nuchal translucency and apparently normal prenatal and/or postnatal assessment: a systematic review. Ultrasound Obstet Gynecol 2012;39:10-9.
71. Miltoft CB, Ekelund CK, Hansen BM, et al. Increased nuchal translucency, normal karyotype and infant development. Ultrasound Obstet Gynecol 2012;39:28-33.
72. Mula R, Gonce A, Bennasar M, et al. Increased nuchal translucency and normal karyotype: perinatal and pediatric outcomes at 2 years of age. Ultrasound Obstet Gynecol 2012;39:34-41.
73. Souka AP, Krampl E, Bakalis S, et al. Outcome of pregnancy in chromosomally normal fetuses with increased nuchal translucency in the first trimester. Ultrasound Obstet Gynecol 2001;18:9-17.
74. Adekunle O, Gopee A, el-Sayed M, et al. Increased first trimester nuchal translucency: pregnancy and infant outcomes after routine screening for Down's syndrome in an unselected antenatal population. Br J Radiol 1999;72:457-60. (Pubitemid 29241582)
75. Cheng CC, Bahado-Singh RO, Chen SC, et al. Pregnancy outcomes with increased nuchal translucency after routine Down syndrome screening. Int J Gynaecol Obstet 2004;84:5-9. (Pubitemid 38064136)
76. Maymon R, Jauniaux E, Cohen O, et al. Pregnancy outcome and infant follow-up of fetuses with abnormally increased first trimester nuchal translucency. Hum Reprod 2000;15:2023-7.
77. Senat MV, Bussieres L, Couderc S, et al. Long-term outcome of children born after a fi rst-trimester measurement of nuchal translucency at the 99th centile or greater with normal karyotype: a prospective study. Am J Obstet Gynecol 2007;96:53. e1-6.
78. Brady AF, Pandya PP, Yuksel B, et al. Outcome of chromosomally normal livebirths with increased fetal nuchal translucency at 10-14 weeks' gestation. J Med Genet 1998;35:222-4. (Pubitemid 28159927)
79. Van Vugt JM, Tinnemans BW, Van Zalen-Sprock RM. Outcome and early childhood follow-up of chromosomally normal fetuses with increased nuchal translucency at 10-14 weeks' gestation. Ultrasound Obstet Gynecol 1998;11:407-9. (Pubitemid 28344742)
80. Poon LC, Karagiannis G, Stratieva V, et al. First-trimester prediction of macrosomia. Fetal Diagn Ther 2011;29:139-47.
81. Weissmann-Brenner A, Weisz B, Lerner-Geva L, et al. Increased nuchal translucency is associated with large for gestational age neonates in singleton pregnancies. J Perinat Med 2011;39:305-9.
82. Syngelaki A, Chelemen T, Dagklis T, et al. Challenges in the diagnosis of fetal non-chromosomal abnormalities at 11-13 weeks. Prenat Diagn 2011;31:90-102.
83. Becker R, Wegner RD. Detailed screening for fetal anomalies and cardiac defects at the 11-13-week scan. Ultrasound Obstet Gynecol 2006;27(6):613-8. (Pubitemid 43967361)
84. Becker R, Schmitz L, Kilavuz S, et al. 'Normal' nuchal translucency: a justification to refrain from detailed scan? Analysis of 6858 cases with special reference to ethical aspects. Prenat Diagn 2012;32:550-6.
85. de Graaf IM, Tijmstra T, Bleker OP, et al.Womens ' preference in Down syndrome screening. Prenat Diagn 2002;22:624-9. (Pubitemid 34839304)
86. Bronshtein M, Zimmer EZ, Blazer S. The utility of detailed first trimester ultrasound examination in abnormal fetal nuchal translucency. Prenat Diagn 2008;28:1037-41. (Pubitemid 352789470)
87. Matias A, Huggon I, Areias JC, et al. Cardiac defects in chromosomally normal fetuses with abnormal ductus venosus blood flow at 10-14 weeks. Ultrasound Obstet Gynecol 1999;14:307-10. (Pubitemid 30032352)
88. Oh C, Harman C, Baschat AA. Abnormal first-trimester ductus venosus blood flow: a risk factor for adverse outcome in fetuses with normal nuchal translucency. Ultrasound Obstet Gynecol 2007;30:192-6. (Pubitemid 47266023)
89. Maiz N, Plasencia W, Dagklis T, et al. Ductus venosus Doppler in fetuses with cardiac defects and increased nuchal translucency thickness. Ultrasound Obstet Gynecol 2008;31:256-60.
90. Bilardo CM, Timmerman E, De Medina PG, et al. Low-resistance hepatic artery flow in first-trimester fetuses: an ominous sign. Ultrasound Obstet Gynecol 2011;37:438-43.
91. Zvanca M, Gielchinsky Y, Abdeljawad F, et al. Hepatic artery Doppler in trisomy 21 and euploid fetuses at 11-13 weeks. renat Diagn 2011;31:22-7.
92. Schuth W, Karck U, Wilhelm C, et al. Parents' needs after ultrasound diagnosis of a fetal malformation: an empirical deficit analysis. Ultrasound Obstet Gynecol 1994;4:124-9.
93. Bilardo CM. Increased nuchal translucency and normal karyotype: coping with uncertainty. Ultrasound Obstet Gynecol 2001;17:99-101.
94. Palomaki GE, Kloza EM, Lambert-Messerlian GM, et al. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med 2011;13:913-20.
95. Bianchi DW, Platt LD, Goldberg JD, et al. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol 2012;119:890-901.
96. Chiu RW, Akolekar R, Zheng YW, et al. Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. BMJ 2011;342:c7401.
97. Nicolaides KH, Syngelaki A, Ashoor G, et al. Noninvasive prenatal testing for fetal trisomies in a routinely screened firsttrimester population. Am J Obstet Gynecol 2012;207:374.e1-6.
98. Verweij EJ, Jacobsson B, van Scheltema PA, et al. European Non-Invasive Trisomy Evaluation (EU-NITE) study: a multicenter prospective cohort study for non-invasive fetal trisomy 21 testing. Prenat Diagn 2013;33:996-1001.